140 related articles for article (PubMed ID: 7232823)
1. Screening of small molecular microbial products modulating immune responses and bestatin.
Umezawa H
Recent Results Cancer Res; 1980; 75():115-25. PubMed ID: 7232823
[TBL] [Abstract][Full Text] [Related]
2. Recent studies on antibiotics and small molecular immunomodulators with potential usefulness in treating lung cancer: Part II - Small molecular weight immunomodulators produced by microorganisms.
Umezawa H
Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):19-23. PubMed ID: 7056602
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight immunomodifiers produced by microorganisms.
Umezawa H; Ishizuka M
Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S9-13. PubMed ID: 3842696
[TBL] [Abstract][Full Text] [Related]
4. Fundamental studies on bestatin: a small molecular microbial product enhancing immune response.
Umezawa H
Recent Results Cancer Res; 1981; 76():209-21. PubMed ID: 7232851
[No Abstract] [Full Text] [Related]
5. Effect of bestatin on mouse immune system and experimental murine tumors.
Ishizuka M; Masuda T; Kanbayashi N; Fukasawa S; Takeuchi T; Aoyagi T; Umezawa H
J Antibiot (Tokyo); 1980 Jun; 33(6):642-52. PubMed ID: 7419475
[TBL] [Abstract][Full Text] [Related]
6. Bestatin treatment and the peripheral lymphocyte population in cancer patients.
Blomgren H; Strender LE; Edsmyr F
Recent Results Cancer Res; 1980; 75():133-8. PubMed ID: 7232824
[TBL] [Abstract][Full Text] [Related]
7. [Low molecular weight immunomodulators produced by microorganisms].
Ishizuka M
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2709-14. PubMed ID: 6508323
[TBL] [Abstract][Full Text] [Related]
8. Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function.
Mathé G
Biomed Pharmacother; 1991; 45(2-3):49-54. PubMed ID: 1912369
[TBL] [Abstract][Full Text] [Related]
9. [Experimental and clinical studies of bestatin as an immunomodulator].
Miwa H; Oka T; Tsurumi T; Sakae Y; Orita K
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1019-24. PubMed ID: 7184437
[TBL] [Abstract][Full Text] [Related]
10. Studies on low-molecular-weight immunomodifiers produced by microorganisms: results of ten years' effort.
Umezawa H
Rev Infect Dis; 1984; 6(3):412-20. PubMed ID: 6234644
[TBL] [Abstract][Full Text] [Related]
11. Small molecular microbial products enhancing immune response.
Umezawa H
Antibiot Chemother (1971); 1978; 24():9-18. PubMed ID: 655681
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor cell invasion by ubenimex (bestatin) in vitro.
Saiki I; Murata J; Watanabe K; Fujii H; Abe F; Azuma I
Jpn J Cancer Res; 1989 Sep; 80(9):873-8. PubMed ID: 2513304
[TBL] [Abstract][Full Text] [Related]
13. Bestatin as an experimental tool in mammals.
Scornik OA; Botbol V
Curr Drug Metab; 2001 Mar; 2(1):67-85. PubMed ID: 11465152
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic and hematologic properties of bestatin in normal and cyclophosphamide myelosuppressed mice.
Talmadge JE; Black PL; Pelus LM; Abe F
Biomed Pharmacother; 1990; 44(2):85-91. PubMed ID: 2224059
[TBL] [Abstract][Full Text] [Related]
15. Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity.
Inoi K; Goto S; Nomura S; Isobe K; Nawa A; Okamoto T; Tomoda Y
Anticancer Res; 1995; 15(5B):2081-7. PubMed ID: 8572606
[TBL] [Abstract][Full Text] [Related]
16. Effect of bestatin on syngeneic tumors in mice.
Abe F; Shibuya K; Uchida M; Takahashi K; Horinishi H; Matsuda A; Ishizuka M; Takeuchi T; Umezawa H
Gan; 1984 Jan; 75(1):89-94. PubMed ID: 6586596
[TBL] [Abstract][Full Text] [Related]
17. A review of clinical studies of bestatin.
Oka S
Recent Results Cancer Res; 1980; 75():126-32. PubMed ID: 7015425
[TBL] [Abstract][Full Text] [Related]
18. The antitumor effect of bleomycin combined with bestatin against Ehrlich ascites carcinoma in mice.
Kaya G; Akin C; Altuğ T; Devrim S
Proc Soc Exp Biol Med; 1988 Mar; 187(3):292-5. PubMed ID: 2450356
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of immune responses and possible inhibition of suppressor cells by aclacinomycin A.
Ishizuka M; Takeuchi T; Masuda T; Fukasawa S; Umezawa H
J Antibiot (Tokyo); 1981 Mar; 34(3):331-40. PubMed ID: 6456249
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic and therapeutic properties of bestatin in normal and myelosuppressed mice.
Talmadge JE; Pelus LM; Black PL; Abe F
Biomed Pharmacother; 1991; 45(2-3):61-9. PubMed ID: 1912371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
